News for BridgeBio Pharma, Inc. (BBIO)

BridgeBio (BBIO) has received a positive boost from H.C. Wainwright as the analyst Raghuram Selvaraju raised the stock's price target to $53, up from the previo

Summary BridgeBio Pharma Inc (BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, announced on April 11, 2025, that its board's com

BridgeBio Pharma (BBIO) announces inducement grants for new employees totaling 77,652 shares. Vesting schedule includes 25% vesting on May 16, 2026, fol

**media[592906]**

BridgeBio Pharma (BBIO) shows a promising 22.56% increase year-to-date, highlighting its potential in the biotech industry. Analysts predict an average

**media[581647]**

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

**media[578214]**

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.

BridgeBio Pharma Inc (BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, announced on March 21, 2025, that its board's compensatio

PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ( BBIO) (”œBridgeBio” or the ”œCompany”), a commercial-stage biopharmaceuti

**media[573317]**

BridgeBio Pharma Inc (BBIO), a biopharmaceutical company dedicated to developing transformative medicines for genetic diseases, announced on March 17, 2025, the

PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ( BBIO) (”œBridgeBio” or the ”œCompany”), a new type of biopharmaceutical c

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq under the ticker symbol BBOT. Read more here.

BridgeBio Pharma Inc (BBIO), a biopharmaceutical company focused on genetic diseases, announced on February 25, 2025, the pricing of $500 million in convertible

**media[550513]**

On February 24, 2025, BridgeBio Pharma Inc (BBIO) announced its intention to offer $500 million in convertible senior notes due 2031 in a private offering to qu